Literature DB >> 29985706

Growing Number Of Unsubsidized Part D Beneficiaries With Catastrophic Spending Suggests Need For An Out-Of-Pocket Cap.

Erin Trish1, Jianhui Xu2, Geoffrey Joyce3.   

Abstract

Medicare Part D has no cap on beneficiaries' out-of-pocket spending for outpatient prescription drugs, and, unlike Medicare Parts A and B, beneficiaries are prohibited from purchasing supplemental insurance that could provide such a cap. Historically, most beneficiaries whose annual Part D spending reached the catastrophic level were protected from unlimited personal liability by the Low-Income Subsidy (LIS). However, we found that the proportion of beneficiaries whose spending reached that level but did not qualify for the subsidy-and therefore remained liable for coinsurance-increased rapidly, from 18 percent in 2007 to 28 percent in 2015. Moreover, average total per person per year spending grew much more rapidly for those who did not qualify for the LIS than for those who did, primarily because of differences in price and utilization trends for the drugs that represented disproportionately large shares of their spending. We estimated that a cap for all Part D enrollees in 2015 would have raised monthly premiums by only $0.40-$1.31 per member.

Entities:  

Keywords:  Cost of Health Care; Health Spending; Insurance; Medicare; Pharmaceuticals

Mesh:

Substances:

Year:  2018        PMID: 29985706      PMCID: PMC7268910          DOI: 10.1377/hlthaff.2018.0006

Source DB:  PubMed          Journal:  Health Aff (Millwood)        ISSN: 0278-2715            Impact factor:   6.301


  5 in total

1.  Benefit design and specialty drug use.

Authors:  Dana P Goldman; Geoffrey F Joyce; Grant Lawless; William H Crown; Vincent Willey
Journal:  Health Aff (Millwood)       Date:  2006 Sep-Oct       Impact factor: 6.301

2.  Long-term trends in the concentration of Medicare spending.

Authors:  Gerald F Riley
Journal:  Health Aff (Millwood)       Date:  2007 May-Jun       Impact factor: 6.301

3.  In-gap discounts in Medicare Part D and specialty drug use.

Authors:  Jeah Jung; Wendy Yi Xu; Chelim Cheong
Journal:  Am J Manag Care       Date:  2017-09       Impact factor: 2.229

4.  Medicare Program; Contract Year 2019 Policy and Technical Changes to the Medicare Advantage, Medicare Cost Plan, Medicare Fee-for-Service, the Medicare Prescription Drug Benefit Programs, and the PACE Program. Final rule.

Authors: 
Journal:  Fed Regist       Date:  2018-04-16

5.  Association of Prescription Drug Price Rebates in Medicare Part D With Patient Out-of-Pocket and Federal Spending.

Authors:  Stacie B Dusetzina; Rena M Conti; Nancy L Yu; Peter B Bach
Journal:  JAMA Intern Med       Date:  2017-08-01       Impact factor: 21.873

  5 in total
  4 in total

1.  Medicare Part D: Time for Re-Modernization?

Authors:  Erin E Trish
Journal:  Health Serv Res       Date:  2019-10-30       Impact factor: 3.402

2.  Closing the Part D Coverage Gap and Out-of-Pocket Costs for Multiple Sclerosis Drugs.

Authors:  Daniel M Hartung; Kirbee A Johnston; Dennis N Bourdette; Randi Chen; Chien-Wen Tseng
Journal:  Neurol Clin Pract       Date:  2021-08

3.  Assessment of Expected Out-of-Pocket Spending for Rheumatoid Arthritis Biologics Among Patients Enrolled in Medicare Part D, 2010-2019.

Authors:  Alexandra Erath; Stacie B Dusetzina
Journal:  JAMA Netw Open       Date:  2020-04-01

4.  Association of Branded Prescription Drug Rebate Size and Patient Out-of-Pocket Costs in a Nationally Representative Sample, 2007-2018.

Authors:  Kai Yeung; Stacie B Dusetzina; Anirban Basu
Journal:  JAMA Netw Open       Date:  2021-06-01
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.